Akeso, Inc. Completes Series-D Private Financing for US$150 Million - PR Newswire APAC
Summary
Xia Yu, CEO, President and founder of Akeso said, "We are very honoured to have received recognition and support from top investment institutions in biopharmaceutical industries both domestically and internationally. Akeso has developed a broad and innovative portfolio in both oncology and immunology therapeutic areas, and is showing promising results in clinical trials. In the coming few years, we look forward to sharing our experience and resources with Akeso Biopharma and supporting the company in becoming the worlds leading innovative, pharmaceutical R&D firm," said Loyal Valley Capitals managing partner Lin Lijun.Tse Hsin, vice president of Sino Biopharm, said: "After our subsidiary Chia TaiTianqing Pharmaceutical and Akeso Biopharma reached a cooperation agreement in June, this is our yet another deep collaboration with the company, and Sino Biopharms first pre-IPO where it leads in investment as one of the innovative, domestic biopharmaceutical players. We look forward to offering the company long-term support for strengthening product development and creating greater commercial value," Dr Li Bin, founder of Lake Bleu Capital, said.Li Hongxing, managing Director CDG International said, "Chinas innovative medicine industry, especially the market for innovative anti-tumour biomedicines and immunotherapy, has huge growth potential. Akeso Biopharma possesses industry-wide R&D capabilities and built cGMP production lines meeting NMPA, EMA and FDA standards ages ago.